BRAF and Miyoshi myopathy: The small molecules trametinib (T), cobimetinib (C), and binimetinib (B) have been extensively investigated in association with BRAF‐i in large first‐line phase III trials enrolling untreated MM patients with BRAFv600 mutation (Robert et al. 2015; Dummer et al. 2022; Ascierto et al. 2016), improving progression‐free survival (PFS) and overall survival (OS) as well as the response rate (RR) versus single‐agent therapy (Dummer et al. 2018; Malki and Pearson 2020).